Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Lowers Price Target to $578

Benzinga Newsdesk www.benzinga.com Negative 59.4%

Neg 59.4% Neu 0% Pos 0%

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and lowers the price target from $587 to $578.